Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating tezepelumab (210 mg) or placebo subcutaneously every 4 weeks for 52 weeks in patients (12 to 80 years of age) with asthma.
Primary outcome measures:
Annualized rate of asthma exacerbations over a period of 52 weeks.
The authors concluded that patients with severe, uncontrolled asthma who received tezepelumab had fewer exacerbations and better lung function, asthma control, and health-related quality of life than those who received placebo
…